A Phase Ib Single-arm, Open-label, Multicenter Study to Assess the Safety and Tolerability of Combined Treatment With Nilotinib 300mg BID and Ruxolitinib Increasing Dose in CML and Ph+ ALL Patients

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 06 Nov 2021

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Nilotinib (Primary) ; Ruxolitinib (Primary)
Indications Chronic myeloid leukaemia; Precursor cell lymphoblastic leukaemia-lymphoma
Focus Adverse reactions
Acronyms CoRNea
Sponsors Novartis Pharmaceuticals

30 Sep 2018 Status changed from active, no longer recruiting to completed.
11 May 2018 Planned End Date changed from 8 Aug 2019 to 19 Aug 2019.
11 May 2018 Planned primary completion date changed from 8 Aug 2019 to 18 Feb 2019.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com